Home | Welcome to Contract Pharma   
Last Updated Wednesday, October 1 2014
Print

Financial Report: Hospira



Published May 1, 2013
Hospira

1Q Revenues: $884.0 million (-9%)

1Q Loss: $76.6 million (earnings were $40.2 million 1Q12)

Comments: Specialty Injectable Pharmaceuticals sales were $651.5 million, up 11%. Medication Management revenues dropped 51% to $124.5 million. Other Pharma sales were $108.0 million, down 12%. Certain quality and product related charges primarily include third party oversight and consulting costs, extended production downtime related costs, failure to supply penalties, device product review and remediation costs to address identified issues, and costs for corrective actions including product recalls.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On